Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1Completed 1Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 3CNS 3Thoracic 2Other hematologic neoplasm 2Head & Neck 2Tumor-Agnostic 1Plasma cell 1Lymphoid 1Gynecologic 1Genitourinary 1Gastrointestinal 1Endocrine 1Breast 1

Conditions

Neoplasm Metastasis 1

Interventions

pembrolizumab 17Specimen Handling 9Magnetic Resonance Spectroscopy 9Bevacizumab 8Paclitaxel 7Biopsy 7Nivolumab 6atezolizumab 5Surveys and Questionnaires 4Standard of Care 4Radiosurgery 4Practice Guidelines as Topic 4Pemetrexed 4Oxaliplatin 4Cyclophosphamide 4Carboplatin 4osimertinib 3niraparib 3durvalumab 3cemiplimab 3avelumab 3Radiotherapy 3Radiation 3Leucovorin 3Irinotecan 3Ipilimumab 3Interviews as Topic 3Fluorouracil 3trastuzumab deruxtecan 2trametinib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × omipalisib × Tumor-Agnostic × Clear all
NCT02079740 2026-05-28

Trametinib and Navitoclax in Treating Patients With Advanced or Metastatic Solid Tumors

National Cancer Institute (NCI)

Phase 1/2 Active not recruiting
96 enrolled 30 charts
Tumor-Agnostic

Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡